NI-308

Drug Name: NI-308
Company: Neurimmune Therapeutics
Location: Switzerland
Website: http://www.neurimmune.com
Drug Type: Protein Biologic
Conditions: ALS, FTD
Mechanism Type: Not Disclosed
Mechanism: NI-308 is a human-derived monoclonal antibody that targets an undisclosed target for ALS/FTD.
U.S. Status for ALS: Preclinical

References:
[1] Neurimmune. Product Pipeline. Neurimmune, 2016. Accessed 11 Mar 2016 from http://www.neurimmune.com/products/product-pipeline.html
[2] NeurImmune allies with Biogen. European Biotechnology. 2 Jun 2011. Accessed 11 Mar 2016 from http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/9/article/neurimmune-allies-with-biogen.html

Last updated March 11th, 2016

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail